Leerink Resumes Genmab A/S (GMAB) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts GMAB Hot Sheet
Price: $39.57 +1.28%
Rating Summary:
12 Buy, 2 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
12 Buy, 2 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
Leerink analyst Asthika Goonewardene resumes coverage on Genmab A/S (NASDAQ: GMAB) with a Outperform rating and a price target of $50.00.
For an analyst ratings summary and ratings history on Genmab A/S click here. For more ratings news on Genmab A/S click here.
Shares of Genmab A/S closed at $34.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott Labs (ABT) PT Lowered to $125 at BTIG
- Southern Missouri Bancorp (SMBC) Tops Q1 EPS by 7c
- Deepseek Raises $15 Bln In Funding Deal Joined By Tencent, Catl - Bloomberg
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
